%0 Journal Article
%T Smoldering multiple myeloma: taking the narrow over the wide path?
%A Avet-Loiseau H
%A Bahlis NJ
%J Blood
%V 143
%N 20
%D 2024 May 16
%M 38427775
%F 25.476
%R 10.1182/blood.2024023880
%X <B>UNASSIGNED: </B>Smoldering multiple myeloma (MM) is an asymptomatic clonal plasma cell condition considered as a premalignant entity that may evolve over time to symptomatic MM. Based on a "poorly defined" risk of progression, some well-intended investigators proposed prospective interventional trials for these individuals. We believe this may be a harmful intervention and favor a close "wait and watch" approach and rather enroll these patients in dedicated observational biological studies aiming to better identify patients who will evolve to MM, based on their plasma cells' biology, including genomics, epigenetics, and the immune microenvironment.